Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

17 September 2020: Clinical Research

Comparison of Clinical Outcomes in Patients with ST Elevation Myocardial Infarction with Percutaneous Coronary Intervention and the Use of a Telemedicine App Before and After the COVID-19 Pandemic at a Center in Beijing, China, from August 2019 to March 2020

Jing Nan 1ABCDEG* , Shuai Meng 1BCE* , Hongyu Hu 1CDE , Ruofei Jia 1DEF , Wei Chen 1DEF , Qun Li 1DE , Tong Zhang 1DEF , Ke Song 1DEF , Yang Wang 2ACDE* , Zening Jin 1ABDEF*

DOI: 10.12659/MSM.927061

Med Sci Monit 2020; 26:e927061

Table 1 Baseline clinical characteristics of the app user group and non-app user group before and after the COVID-19 pandemic.

Patients before the pandemic (n=183)*p valuePatients after the pandemic (n=60)**p value***p value
App user group (n=25)Non App user group (n=158)App user group (n=8)Non App user group (n=52)
Age (years)68 (51–73.5)66.5 (57–76)0.65667.5 (53.25–81.25)71.5 (56.75–77.75)0.9390.193
Male13 (52%)100 (63.3%)0.3765 (62.5%)32 (61.5%)1.0001.000
Hypertension8 (32%)108 (68.4%)0.0014 (50%)20 (38.5%)0.7020.002
Diabetes7 (28%)76 (48.1%)0.0832 (25%)25 (48.1%)0.2761.000
Dyslipidemia7 (28%)61 (38.6%)0.3773 (37.5%)13 (25%)0.4290.160
Current smoker13 (52%)58 (36.7%)0.1852 (25%)16 (30.8%)1.0000.280
Prior myocardial infarction5 (20%)18 (11.4%)0.3252 (25%)6 (11.5%)0.2880.827
Prior percutaneous coronary intervention7 (28%)19 (12.0%)0.0581 (12.5%)5 (9.6%)1.0000.512
Previous coronary artery bypass surgery0 (0%)1 (0.6%)1.0001 (13.3%)0 (0%)0.1330.434
Previous cerebrovascular event5 (20%)42 (26.6%)0.6252 (25%)4 (7.7%)0.1780.011
Chronic renal failure (estimated glomerular filtration rate1 (4%)11 (6.3%)1.0000 (0%)7 (13.5%)0.5780.265
Premature CAD history1 (4%)23 (14.6%)0.2070 (0%)5 (9.6%)1.0000.369
Killip classification ≥210 (40%)64 (40.5%)1.0004 (50%)32 (61.5%)0.7020.011
Lab test
Peak cTn-I162.6±16.87166.4±20.170.12081.78±32.04103.93±34.960.0970.060
BNP on admission303 (202.8–408)301.5 (197.88–410.5)0.969328 (197.75–416)303 (210–408.25)0.9130.626
Left ventricular ejection fraction (%)47 (42–53)47 (40.5–52.5)0.54146 (39.5–51.75)45.5 (41.25–55)0.7110.677
Baseline medication
Aspirin12 (48%)46 (29.1%)0.0682 (25%)13 (25%)1.0000.417
ADP receptor antagonist1 (4%)9 (5.7%)1.0001 (12.5%)5 (9.6%)1.0000.235
Oral anticoagulant4 (16%)30 (19%)1.0001 (12.5%)16 (30.8%)0.4200.143
Statin7 (28%)59 (37.3%)0.5023 (37.5%)14 (26.9%)0.6760.347
ACEI or ARB4 (16%)37 (23.4%)0.6061 (12.5%)7 (13.5%)1.0000.142
β blocker2 (8%)23 (14.6%)0.5371 (12.5%)2 (3.8%)0.3540.100
Frequencies are reported as n/total (%), unless otherwise specified. CAD – cardiovascular disease; BNP – B-type natriuretic peptide; ADP – adenosine diphosphate; ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker.
* Comparison between App user and non-App user group after the pandemic;
** comparison between App user and non-App user group after the pandemic;
*** comparison between patients before and after the pandemic.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750